Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 25;63(5):e02533-18.
doi: 10.1128/AAC.02533-18. Print 2019 May.

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

Rima K Acosta  1 , Madeleine Willkom  2 , Ross Martin  2 , Silvia Chang  2 , Xuelian Wei  2 , William Garner  2 , Justin Lutz  2 , Sophia Majeed  2 , Devi SenGupta  2 , Hal Martin  2 , Erin Quirk  2 , Kirsten L White  2
Affiliations

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

Rima K Acosta et al. Antimicrob Agents Chemother. .

Abstract

In clinical studies GS-US-380-1489 (study 1489) and GS-US-380-1490 (study 1490), bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF), dolutegravir-abacavir-lamivudine (DTG-ABC-3TC), and dolutegravir plus emtricitabine-tenofovir alafenamide (DTG+F-TAF) treatment achieved high rates of virologic suppression in HIV-1 treatment-naive participants through week 48. Preexisting primary drug resistance was present at levels of 1.3% integrase strand transfer inhibitor resistance (INSTI-R), 2.7% nucleoside reverse transcriptase inhibitor resistance (NRTI-R), 14.1% nonnucleoside reverse transcriptase inhibitor resistance (NNRTI-R), and 3.5% protease inhibitor resistance (PI-R) in the 1,274 participants from these studies. These mutations did not affect treatment outcomes. Resistance analyses in 13 virologic failures found no emergent resistance to study drugs.

Keywords: bictegravir; clinical trial; resistance; treatment naive.

PubMed Disclaimer

Figures

FIG 1
FIG 1
HIV-1 RNA results for participant with transmitted Q148H plus G140S in IN and K70R and K103N in RT and treated with B-F-TAF. The dotted line represents plasma HIV-1 RNA equal to 50 copies/ml. Plasma HIV-1 RNA values below 20 copies/ml are qualified as <20 copies/ml HIV-1 RNA detected or no HIV-1 RNA detected in this assay and are plotted here as 20 copies/ml or 10 copies/ml, respectively.
See this image and copyright information in PMC

References

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2018. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services, Washington, DC.
    1. European AIDS Clinical Society (EACS). 2017. Guidelines, version 9.0. (English). European AIDS Clinical Society, London, United Kingdom.
    1. Gilead Sciences, Inc. 2018. BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use, package insert. Gilead Sciences, Inc., Foster City, CA.
    1. Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, Niedziela-Majka A, Yant SR, Yu H, Kukolj G, Cihlar T, Lazerwith SE, White KL, Jin H. 2016. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother 60:7086–7097. doi:10.1128/AAC.01474-16. - DOI - PMC - PubMed
    1. Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. 2017. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 390:2063–2072. doi:10.1016/S0140-6736(17)32299-7. - DOI - PubMed

MeSH terms